Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: Rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study

European Journal of Heart Failure

Volumn 13, Issue 1, 2011, Pages 107-114

  Krum, Henry ^a   Massie, Barry ^b   Abraham, William T ^c   Dickstein, Kenneth ^d,e   Kober, Lars ^f   McMurray, John J V ^g   Desai, Ashkay ^h   Gimpelewicz, Claudio ⁱ   Kandra, Albert ⁱ   Reimund, Bernard ⁱ   Rattunde, Henning ⁱ   Armbrecht, Juergen ⁱ  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d STAVANGER UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF BERGEN   (Norway)

^f Rigshospitalet   (Denmark)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ACE inhibitor; Aliskiren; Chronic heart failure; Renin; Reninangiotensin

Indexed keywords

ALISKIREN; BRAIN NATRIURETIC PEPTIDE; ENALAPRIL; RENIN;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME;

AMIDES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENALAPRIL; FUMARATES; HEART FAILURE, SYSTOLIC; HUMANS; NATRIURETIC PEPTIDE, BRAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN; RENIN-ANGIOTENSIN SYSTEM; RESEARCH DESIGN; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 78650380191     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq212     Document Type: Article

References (27)

1. Lloyd-Jones D Adams RJ Brown TM Carnethon M Dai S De Simone G Ferguson TB Ford E Furie K Gillespie C Go A Greenlund K Haase N Hailpern S Ho PM Howard V Kissela B Kittner S Lackland D Lisabeth L Marelli A McDermott MM Meigs J Mozaffarian D Mussolino M Nichol G Roger VL Rosamond W Sacco R Sorlie P Stafford R Thom T Wasserthiel-Smoller S Wong ND Wylie-Rosett J; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010;121:e46-e215.
2. Dickstein K Cohen-Solal A Filippatos G McMurray JJ Ponikowski P Poole-Wilson PA Strömberg A van Veldhuisen DJ Atar D Hoes AW Keren A Mebazaa A Nieminen M Priori SG Swedberg K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10: 933-989.
3. Brown NJ Vaughan DE. Prothrombotic effects of angiotensin. Adv Intern Med 2000;45:419-429.
4. Burnier M Brunner HR. Angiotensin II receptor antagonists. Lancet 2000;355: 637-645.
5. Cohn JN. Current concepts in the treatment of congestive heart failure. Cardiology 1997;88(Suppl 2):2-6.
6. Cohn JN Johnson G Ziesche S Cobb F Francis G Tristani F Smith R Dunkman WB Loeb H Wong M Bhat G Goldman S Fletcher RD Doherty J Hughes CV Carson P Cintron G Shabetai R Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
7. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
8. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
9. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
10. Hollenberg NK Fisher ND Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32:387-392.
11. Karlberg BE. Cough and inhibition of the renin-angiotensin system. J Hypertens Suppl 1993;11:S49-S52.
12. Wood JM Maibaum J Rahuel J Grütter MG Cohen NC Rasetti V Rüger H Göschke R Stutz S Fuhrer W Schilling W Rigollier P Yamaguchi Y Cumin F Baum HP Schnell CR Herold P Mah R Jensen C O'Brien E Stanton A Bedigian MP. Structure-based design of aliskiren a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003;308:698-705.
13. Nussberger J Wuerzner G Jensen C Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002;39:E1-E8.
14. Latini R Masson S Anand I Salio M Hester A Judd D Barlera S Maggioni AP Tognoni G Cohn JN; Val-HeFT Investigators. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004;25:292-299.
15. Waldmeier F Glaenzel U Wirz B Oberer L Schmid D Seiberling M Valencia J Riviere GJ End P Vaidyanathan S. Absorption distribution metabolism and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007;35:1418-1428.
16. Seed A Gardner R McMurray J Hillier C Murdoch D MacFadyen R Bobillier A Mann J McDonagh T. Neurohumoral effects of the new orally active renin inhibitor aliskiren in chronic heart failure. Eur J Heart Fail 2007;9:1120-1127.
17. McMurray JJ Pitt B Latini R Maggioni AP Solomon SD Keefe DL Ford J Verma A Lewsey J; Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24.
18. McMurray JJ Ostergren J Swedberg K Granger CB Held P Michelson EL Olofsson B Yusuf S Pfeffer MA; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-771. (Pubitemid 37093916)
19. Garg R Yusuf S. Overview of randomised trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450.
20. Bretz F Maurer W Brannath W Posch M. A graphical approach to sequentially rejective multiple test procedures. Stat Med 2009;28:586-604.
21. Cowie MR Mendez GF. BNP and congestive heart failure. Prog Cardiovasc Dis 2002;44:293-321.
22. Anand IS Fisher LD Chiang YT Latini R Masson S Maggioni AP Glazer RD Tognoni G Cohn JN; Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-1283.
23. Zannad F McMurray JJ Krum H van Veldhuisen DJ Swedberg K Shi H Vincent J Pocock S Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med doi:10.1056/nejmoa1009492. Published online ahead of print 14 November 2010.
24. Swedberg K Komajda M Böhm M Borer JS Ford I Dubost-Brama A Lerebours G Tavazzi L; on behalf of the SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-885.
25. ONTARGET Investigators Yusuf S Teo KK Pogue J Dyal L Copland I Schumacher H Dagenais G Sleight P Anderson C. Telmisartan ramipril or both in patients at high risk for vascular events. N Engl J Med 2008;358: 1547-1559.
26. Cohn JN Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
27. Konstam MA Neaton JD Dickstein K Drexler H Komajda M Martinez FA Riegger GA Malbecq W Smith RD Guptha S Poole-Wilson PA; HEAAL Investigators. Effects of high-dose vs. low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised double-blind trial. Lancet 2009; 374:1840-1848.